On Tuesday, Beta Bionics got an upgrade to its Relative Strength (RS) Rating, from 76 to 84.
Hone Your Stock-Picking Skills By Focusing On These Factors
This exclusive rating from Investor's Business Daily measures share price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
History shows that the stocks that go on to make the biggest gains typically have an RS Rating of over 80 as they launch their biggest runs.
Beta Bionics is not currently near a potential buying area. See if the stock goes on to form a base that could launch a new move.
Beta Bionics posted 0% EPS growth in the latest quarterly report. Sales increased 54%.
The company holds the No. 43 rank among its peers in the Medical-Products industry group. Insulet, TransMedics Group and Axogen are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
